Health In Tech, Inc. (HIT) Stock Forecast
HIT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $3.12 average of analyst targets
- Upside to target
- +378.0% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.06
- 52-week range
- $0.63 – $3.17
HIT analyst ratings
2 analystsNumber of analysts at each rating.
HIT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HIT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.04 | −$0.06 | −$0.03 | $0.01 | −550.0% | 2 |
| Current fiscal year (2026) | −$0.16 | −$0.20 | −$0.12 | $0.02 | −900.0% | 2 |
| Next fiscal year (2027) | −$0.02 | −$0.14 | $0.10 | −$0.16 | +87.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HIT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.4M | $6.4M | $6.5M | −24.2% | 2 |
| Current fiscal year (2026) | $31.8M | $30.6M | $33.0M | −4.6% | 2 |
| Next fiscal year (2027) | $54.1M | $34.0M | $78.0M | +70.2% | 3 |
HIT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HIT revenue: reported and forecast
HIT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.01 | −$0.04 | −$0.04 | −$0.04 | +238.3% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.06 | −$0.06 | −$0.11 | −$0.11 | −$0.16 | +182.2% | 0 up · 0 down |
| Next fiscal year (2027) | $0.14 | $0.14 | $0.04 | $0.04 | −$0.02 | −114.0% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HIT earnings surprises
Reported EPS vs the consensus estimate for the last 7 quarters; HIT beat in 4 of 6.
What analysts expect from HIT
2 analysts cover Health In Tech; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.12, 378.0% above the latest close of $0.65. Analysts expect earnings of −$0.16 per share for 2026, −900.0% from a year earlier. For 2027 the average estimate is −$0.02 per share on revenue of $54.1 million. Health In Tech beat the EPS estimate in 4 of the last 6 quarters.
Related: HIT income statement, HIT key metrics, HIT chart. See the HIT stock overview for the latest quote and news.
HIT forecast FAQ
What is Health In Tech's price target?
The average analyst price target for Health In Tech is $3.12, 378.0% above the latest close of $0.65.
Is Health In Tech a buy, hold or sell?
Of 2 analysts covering Health In Tech, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Health In Tech's EPS forecast?
Analysts forecast −$0.16 per share for 2026 (range −$0.20 to −$0.12); for 2027 the estimate is −$0.02.
What is Health In Tech's revenue forecast?
The average revenue estimate for 2026 is $31.8 million, growth of −4.6%; for 2027 it is $54.1 million.
When does Health In Tech report earnings?
Health In Tech is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.06.
Does Health In Tech usually beat earnings estimates?
Health In Tech reported EPS at or above the analyst estimate in 4 of the last 6 quarters.